SAN DIEGO

,

April 22, 2021

/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the first quarter ended March 31, 2021 as follows:

The live webcast and related slide presentation can be accessed through the Investors section of its

website

or directly at

https://evofem.investorroom.com/2021Q1Results

. Please connect to the Company’s website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.

The webcast will be archived at

https://evofem.investorroom.com/2021Q1Results

. A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 1899453.

About Evofem Biosciences


Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product,

Phexxi®

contraceptive vaginal gel, in the United States in September 2020. Evofem’s lead product candidate, EVO100, is being evaluated for the prevention of urogenital

Chlamydia trachomatis

and

Neisseria gonorrhoeae

infection in women in the ongoing Phase 3 clinical trial,

‘EVOGUARD

.’ For more information, please visit

evofem.com

.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.



[email protected]



Mobile: (917) 673-5775

View original content to download multimedia:

http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2021-results-and-provide-corporate-update-on-thursday-may-6-2021-301274348.html

SOURCE Evofem Biosciences, Inc.